A Research Guide for
TGA, TEA, TIA & Related Conditions

Your evaluation will typically include:

• Vital signs and glucose check: Low blood sugar (hypoglycemia) is a rapidly reversible mimic that must be checked immediately.
• Neurological exam: Testing for weakness, speech problems, vision changes, and coordination — these focal signs point toward TIA/stroke.
• Blood tests: Basic labs, glucose, blood counts, and potentially cardiac markers.
• ECG/heart rhythm monitoring: To check for atrial fibrillation or other heart rhythm problems that could cause reduced blood flow to the brain.
• Brain imaging (CT scan): Usually done first to rapidly rule out bleeding in the brain.
• CT Angiography (CTA): If TIA is suspected, to check blood vessels in the neck and brain for blockages or narrowing.

A specialized MRI using diffusion-weighted imaging (DWI) is the most important imaging test for distinguishing these conditions. It can:

• Confirm TGA: Detect tiny bright “dots” (1–3 mm punctate lesions) in the hippocampus (the brain’s memory center, specifically the CA1 region). These are best seen 24–72 hours after the episode — scans done in the first few hours may be falsely normal.
• Identify TIA/stroke: Detect areas of acute ischemia (reduced blood flow) that confirm a vascular cause.

Timing matters. If your scan was done very early (within 6–12 hours) and was negative, your doctor may recommend a follow-up MRI at 24–72 hours to maximize detection of hippocampal lesions. Studies show detection rates increase from about 46% early on to up to 85% at optimal timing with high-field MRI.

A normal MRI does not rule out TGA — the diagnosis can still be made clinically if the history fits the established criteria.

If TEA is suspected (recurrent episodes, brief duration, episodes on waking), an electroencephalogram (EEG) is essential. This test records brain wave activity to look for seizure-related patterns.

• Standard EEG: Often normal between TEA episodes (only about 35% show abnormalities).
• Sleep-deprived EEG: Increases detection of subtle temporal lobe epileptiform discharges. You stay awake overnight before the test.
• Ambulatory EEG (24–72 hours): Worn at home, captures brain activity during sleep and waking — the highest yield for detecting TEA.

A normal EEG does not rule out TEA. If clinical suspicion is high, your doctor may try anti-seizure medication as a diagnostic trial — if episodes stop, this confirms the diagnosis.

Several common medications can cause transient amnesia that mimics TGA or TEA. Your doctor should review all medications including:

• Benzodiazepines (e.g., lorazepam, diazepam, alprazolam)
• Z-drugs / sleep aids (e.g., zolpidem/Ambien, eszopiclone)
• Anticholinergic medications (some allergy, bladder, and antidepressant medications)
• Opioid pain medications
• Alcohol — especially heavy use or withdrawal

If a medication is the cause, adjusting or stopping it (under medical supervision) resolves the problem.

• Exact start time and duration of the episode
• What you were doing when it started (exercise, straining, emotional stress, cold water, medical procedure)
• Specific repeated questions you asked
• Any physical symptoms: weakness, numbness, speech difficulty, vision changes, lip-smacking, unusual smells or tastes
• Time of day (on waking? during activity?)
• Has this happened before? How many times?
• Complete medication list including over-the-counter drugs and supplements
• Recent alcohol use or sleep deprivation
• Video recording of the episode if available

• Did my MRI show any hippocampal lesions (DWI dots)? Was it done in the optimal 24–72 hour window?
• Do I need a follow-up MRI if the first was done very early?
• Should I have an EEG? What type (standard, sleep-deprived, ambulatory)?
• Could any of my current medications be causing memory episodes?
• Do I need vascular imaging (carotid ultrasound, CTA, or MRA)?
• Should I have heart rhythm monitoring for atrial fibrillation?
• What is my ABCD2 score and what does it mean for my stroke risk?

The exact cause remains debated, and this is an area of genuine scientific uncertainty. The leading theories include:

• Hippocampal vulnerability: The CA1 neurons in the hippocampus (the brain’s memory center) are uniquely sensitive to metabolic stress. During TGA, these neurons temporarily malfunction, disrupting memory formation.
• Venous congestion theory: Case-control vascular studies (primarily from European and Asian research groups) suggest that incompetent valves in the internal jugular veins may allow blood to flow backward during physical strain (Valsalva maneuver), temporarily congesting the veins draining the hippocampus. Studies have found jugular valve incompetence in 74–80% of TGA patients compared to 25–34% of controls, though a causal link remains unproven.
• Cortical spreading depression: Similar to the wave of electrical activity seen in migraine aura, a spreading depression wave may temporarily suppress hippocampal function.

Common triggers include heavy lifting or straining, vigorous exercise, sexual activity, sudden immersion in cold or hot water, strong emotional stress, and medical procedures.

• Sudden onset of inability to form new memories
• Repetitive questioning — the hallmark symptom (“What day is it?” asked every few minutes)
• Appears perplexed or anxious but otherwise “normal”
• Personal identity is always preserved (“I know who I am”)
• Can still perform complex learned tasks (driving, cooking, playing an instrument)
• Older memories may be temporarily inaccessible but return as the episode resolves
• No weakness, no speech difficulty, no vision changes
• Duration typically 2–8 hours (median about 4–6 hours), always under 24 hours
• After resolution: a permanent “gap” for the period of the episode, but no ongoing memory problems

TGA is diagnosed using the Hodges & Warlow criteria (the medical standard since 1990):

1. Attack witnessed and information available from a capable observer
2. Clear anterograde amnesia during the attack
3. No clouding of consciousness and no loss of personal identity
4. Cognitive impairment limited to amnesia (no speech problems, no coordination issues)
5. No focal neurological signs
6. No seizure features during or after
7. Resolves within 24 hours
8. No recent head injury or active epilepsy

MRI with DWI showing punctate hippocampal lesions at 24–72 hours supports the diagnosis but is not required if the clinical features clearly fit.

No treatment is needed. TGA resolves on its own. There is no medication to speed recovery, and none is needed to prevent recurrence.

• Recurrence: Most people have only one episode in their lifetime. Recurrence is reported in roughly 8–15% of patients (some studies report up to 18–25% with extended follow-up).
• Long-term effects: Long-term follow-up studies have not shown a clearly increased risk of stroke or dementia compared to people of similar age. Although some large population-based studies have reported possible associations, current guidelines consider TGA benign. You will have a permanent memory gap for the episode itself, but no ongoing memory problems.
• Driving: No formal restriction once the episode has fully resolved and the diagnosis is confirmed (single, typical TGA).

The main “treatment” is education and reassurance for both the patient and family. Vascular risk factor screening (blood pressure, cholesterol, diabetes) is reasonable as these are common in the same age group.

DO:

• Stay calm. Your calm presence is reassuring.
• Gently answer repeated questions. Their brain physically cannot record the answer — they are not being difficult.
• Keep them safe — seated, comfortable, away from hazards.
• Note the exact start time and what they were doing when it started.
• Record a brief video (with their knowledge if possible) — this is invaluable for the medical team.
• Check for stroke signs: Face drooping, Arm weakness, Speech difficulty, Time to call 911 (F.A.S.T.).
• Call the doctor or go to the ER for a first episode.

DO NOT:

• Do not snap at them or say “I just told you that” — this increases distress.
• Do not quiz them repeatedly to “test” their memory.
• Do not let them drive, operate machinery, or leave the house alone.
• Do not give medications unless instructed by a doctor.
• Do not panic — TGA is frightening but almost always resolves completely.

• Does my episode meet the Hodges & Warlow criteria for TGA?
• Was anything on my MRI or other tests that doesn’t fit TGA?
• What are the chances this will happen again?
• Should I avoid any particular triggers (heavy lifting, temperature extremes)?
• Do I need any follow-up testing?
• When is it safe for me to drive and return to work?
• Is there any reason to suspect this was actually TEA or TIA instead?

TEA is diagnosed using the Butler/Zeman criteria:

1. Recurrent witnessed episodes of transient amnesia
2. Cognitive functions other than memory judged intact during typical attacks (by a reliable witness)
3. Evidence for a diagnosis of epilepsy, based on at least one of:
   • Epileptiform abnormalities on EEG
   • Other clinical features of seizures during episodes (e.g., olfactory hallucinations, lip-smacking, brief unresponsiveness)
   • Clear response to anti-seizure medication (episodes stop with treatment)

EEG findings: Standard EEG between attacks is normal in about 65% of TEA patients. Sleep-deprived and ambulatory (24–72 hour) EEG monitoring significantly increases the chance of detecting epileptiform activity in the temporal lobes.

Many TEA patients experience two distinctive memory problems between episodes:

• Accelerated long-term forgetting (ALF): You learn new information normally and can recall it after 30 minutes (passing standard memory tests), but the information fades abnormally fast over days to weeks. This means routine memory tests at the doctor’s office may appear normal, even though you are noticing real memory difficulties in daily life.
• Autobiographical amnesia: Patchy loss of personal memories — vacations, family events, significant life experiences may be forgotten or become vague. This can be distressing.

These features can persist even after seizures are controlled with medication. Specialized neuropsychological testing that evaluates memory over days or weeks (not just 30 minutes) is needed to detect ALF.

Anti-seizure medications are the cornerstone of TEA treatment and are highly effective:

• Lamotrigine: Often first-line in older adults due to excellent tolerability and minimal cognitive side effects. Requires slow dose increase over weeks (risk of rash with rapid titration). Typical dose: 100–200 mg daily.
• Levetiracetam: Can be started quickly. Well tolerated but may cause irritability or mood changes in some patients. Typical dose: 500–1000 mg twice daily.
• Sodium valproate: Highly effective but more side effects (weight gain, tremor, hair thinning). Must be avoided in women of childbearing age due to birth defect risk.

In combined study cohorts, seizures ceased in over 93% of TEA patients with appropriate medication. Often, low doses are sufficient. The response itself helps confirm the diagnosis.

With proper treatment:

• Most patients achieve complete freedom from amnestic episodes
• Long-term follow-up from the TIME project shows stable cognition and normal life expectancy
• Some degree of accelerated forgetting and autobiographical memory gaps may persist but often improves
• Medication is typically continued long-term to prevent recurrence

• Could my recurrent memory episodes be TEA rather than TGA?
• Should I have a sleep-deprived or ambulatory EEG?
• Which anti-seizure medication would you recommend, and why?
• How will we know if the medication is working?
• Should I have neuropsychological testing for accelerated long-term forgetting?
• What are the driving restrictions after a TEA diagnosis?
• Will I need to take medication for life?
• Are there interactions between anti-seizure medication and my other drugs?

Key differences that point toward TIA rather than TGA:

• Focal neurological symptoms: Any weakness on one side, facial drooping, speech difficulty, vision loss, numbness, or coordination problems strongly suggest TIA, not TGA.
• Vascular risk factors: High blood pressure, diabetes, smoking, atrial fibrillation, high cholesterol, and prior vascular disease increase TIA likelihood.
• Duration: TIA symptoms typically last minutes (most resolve within an hour). TGA lasts hours.
• No repetitive questioning: The classic hallmark of TGA (asking the same question repeatedly) is uncommon in TIA.

When in doubt, treat it as TIA. It is always safer to evaluate for a stroke warning than to miss one.

Your doctor may calculate your ABCD2 score to estimate your short-term stroke risk:

• Age ≥60: 1 point
• Blood pressure ≥140/90: 1 point
• Clinical features: Weakness = 2 points; speech only = 1 point
• Duration: ≥60 min = 2 points; 10–59 min = 1 point
• Diabetes: 1 point

Scores of 4 or higher indicate moderate-to-high risk and typically lead to more aggressive treatment, including dual antiplatelet therapy. Important: ABCD2 has modest discrimination and a low score does not mean you are safe. Current guidelines (NICE NG128, ESO) increasingly recommend specialist assessment within 24 hours for all suspected TIA, regardless of score. ABCD2 should not be used to delay urgent evaluation.

If you have had a TIA, your treatment plan will typically include:

• Dual Antiplatelet Therapy (DAPT) for 21 days: Aspirin plus clopidogrel, started within 24 hours, for high-risk non-cardioembolic TIA or minor stroke. Proven by the CHANCE and POINT trials to significantly reduce early stroke risk (NNT approximately 40–50 to prevent one stroke). After 21 days, you transition to a single blood thinner long-term. DAPT is not appropriate for all TIA patients — your doctor will determine if it is right for you.
• Alternative: Aspirin plus ticagrelor for 30 days (THALES trial) may be used in selected patients. The CHANCE-2 trial showed that for patients with certain genetic variants affecting clopidogrel metabolism (CYP2C19 loss-of-function, more common in East Asian populations), ticagrelor-based therapy may be more effective.
• High-intensity statin: Cholesterol-lowering medication (e.g., atorvastatin 40–80 mg) regardless of your cholesterol level.
• Blood pressure control: Target usually below 130/80 mmHg, adjusted individually.
• Diabetes management: Tight glucose and HbA1c control if diabetic.
• Anticoagulation: If atrial fibrillation is found, a blood thinner (usually a DOAC) replaces antiplatelet therapy.
• Carotid surgery or stenting: If significant narrowing (≥50–70%) of the carotid artery is found, intervention is recommended within 2 weeks.
• Lifestyle changes: Stop smoking, regular exercise, Mediterranean-style diet, moderate alcohol, weight management.

TIA management has been shaped by major international research:

• UK EXPRESS trial: Showed that urgent TIA clinics reduced 90-day recurrent stroke from about 10.3% to about 2.1% — an 80% reduction sustained at 10-year follow-up.
• French SOS-TIA trial: Round-the-clock TIA clinics achieved 90-day stroke rates of about 1.24% versus predicted 6%.
• Chinese CHANCE trial: Established the 21-day dual antiplatelet standard that is now globally adopted.
• East Asian considerations: In Japanese and Korean populations, intracranial atherosclerosis (narrowing inside the brain’s arteries) is a more common TIA cause than in Western populations. Guidelines from these countries may emphasize different imaging and treatment approaches.

• What is my ABCD2 score and what does it mean?
• Am I on dual antiplatelet therapy? For how long?
• Have my carotid arteries been checked? Any narrowing?
• Has atrial fibrillation been ruled out? Do I need prolonged heart monitoring?
• What is my blood pressure and cholesterol target?
• When is it safe for me to drive again?
• What should I do if symptoms return? (Call 911 immediately.)
• Should I take aspirin, clopidogrel, or both? What about ticagrelor?
• Do I need cognitive screening for post-TIA cognitive impairment?

Certain medications can cause temporary memory loss that closely mimics TGA. Common culprits include:

• Benzodiazepines (lorazepam, diazepam, alprazolam): Can cause anterograde amnesia, especially at higher doses or in older adults.
• Z-drugs (zolpidem/Ambien, zaleplon, eszopiclone): Sleep aids that can cause complex behaviors and amnesia.
• Anticholinergic drugs: Found in some allergy, bladder, depression, and pain medications.
• Opioids: High doses or combinations can impair memory.

Treatment: Medication review and adjustment under medical supervision. No additional workup needed once the cause is identified.

Some migraines can cause temporary confusion or memory changes, even without a headache. Features suggesting migraine aura include:

• Visual disturbances (flashing lights, zigzag lines, blind spots) that “march” or spread gradually
• Sensory changes (tingling, numbness) that spread from one area to another
• Typical duration 20–60 minutes
• History of migraine or similar episodes
• Often younger patients

Treatment: Migraine prophylaxis if episodes are frequent. Lifestyle modifications (regular sleep, stress management, trigger avoidance).

Sometimes the brain’s “software” temporarily malfunctions even though the “hardware” is fine. This is functional neurological disorder — a real medical condition, not “imagining it.”

• Memory patterns may be inconsistent or don’t follow the typical TGA/TEA pattern
• Loss of personal identity (forgetting who you are) is a red flag for functional amnesia — this does not happen in TGA or TEA
• Often associated with significant psychological stress
• Duration is variable and may be prolonged

Treatment: Specialized FND-informed therapy (cognitive behavioral therapy, physiotherapy). Dedicated FND clinics exist at some major medical centers. Recovery is achievable.

• Hypoglycemia (low blood sugar): Particularly in diabetics on insulin or sulfonylureas. Causes confusion, disorientation, and sometimes amnesia. Resolves rapidly with glucose correction. Always check blood sugar first in the ER.
• Cardiac arrhythmia: Irregular heart rhythms (especially atrial fibrillation) can reduce blood flow to the brain, causing brief episodes of confusion or syncope. May include palpitations, lightheadedness, or brief loss of consciousness. ECG and prolonged cardiac monitoring can detect intermittent arrhythmias.

• Could any of my medications be causing memory episodes?
• Should I have cardiac monitoring to look for arrhythmias?
• Could this be migraine-related even if I didn’t have a headache?
• Is there a reason to suspect functional neurological disorder?
• Are there specialized FND clinics I could be referred to?

Health-related anxiety is extremely common after any episode of sudden memory loss or neurological symptoms. This is a normal response.

• Education reduces fear. Understanding exactly what happened and why is the most effective treatment for anxiety. Ask questions until you feel satisfied with the explanation.
• Normal test results are genuinely reassuring. If your workup shows no signs of stroke, seizure, or structural problems, you can be confident in those results.
• Talk about it. Share your experience with family, friends, or a support group. Consider speaking with a counselor or psychologist if anxiety persists or interferes with daily life.
• Hypervigilance is common. After a TGA or TIA, many people become acutely aware of every minor memory lapse or physical sensation. Most of these are normal and unrelated to your episode.

• TGA (confirmed, single episode): Generally no formal driving restriction once the episode has fully resolved and the diagnosis is confirmed. Avoid driving during the episode itself. Short-term avoidance is clinically prudent.
• TEA (seizure disorder): Treated as epilepsy for driving purposes. In Utah, the typical requirement is at least 3 months seizure-free with appropriate medication before driving can resume. Individual assessment by the Medical Advisory Board may be required. UK rules are stricter (12 months seizure-free for DVLA).
• TIA: Individual assessment based on residual deficits and whether the underlying cause has been treated. In Utah, physician clearance via the Functional Ability Evaluation form is typically required. Commercial drivers follow stricter DOT/FMCSA standards.

Utah specifics: Utah uses a Functional Ability / Safety Assessment Level framework. Seizures and episodic conditions fall under Category E. Utah relies on driver self-reporting and DLD-requested medical evaluations rather than mandatory physician reporting. Your doctor will complete the required forms.

Regardless of your specific diagnosis, these strategies support brain health and vascular health:

• Blood pressure control: Monitor and manage — high blood pressure is the leading modifiable risk factor for stroke.
• Physical activity: 150 minutes per week of moderate exercise (walking, swimming, cycling).
• Mediterranean-style diet: Fruits, vegetables, whole grains, fish, olive oil. Limit processed foods and excess salt.
• Don’t smoke: If you smoke, quitting is the single most impactful change for stroke prevention.
• Moderate alcohol: Excessive alcohol increases stroke risk and can cause amnesia.
• Stay socially and mentally active: Social engagement, learning new skills, and staying mentally stimulated support cognitive resilience.
• Quality sleep: 7–8 hours per night. Sleep deprivation can trigger seizures (TEA) and impairs memory generally.
• Medication adherence: If prescribed blood thinners, statins, anti-seizure medications, or blood pressure drugs, take them consistently. Use a pill organizer or smartphone reminders.

Call 911 immediately if you experience:

• New weakness, numbness, or tingling on one side of the body
• Difficulty speaking or understanding speech
• Sudden vision loss or double vision
• Severe sudden headache (the worst of your life)
• Loss of consciousness or prolonged confusion
• Seizure-like movements (shaking, stiffening)
• Symptoms lasting longer than 24 hours
• A new episode of memory loss with any physical symptoms

Contact your neurologist (non-emergency) if:

• You have another isolated memory episode similar to your first TGA
• TEA episodes return despite medication
• You notice progressive memory difficulties or personality changes
• You have questions about driving clearance

• Help with appointments: Accompany the patient to neurology follow-ups. You may remember details about the episode that the patient cannot.
• Support medication adherence: Help organize medications, set reminders, and track any side effects.
• Watch for mood changes: Anxiety, depression, and health-related worry are common after any neurological event. Encourage professional support if needed.
• Track episodes: Keep a simple log of any new symptoms, with date, time, duration, and what happened. A phone app or notebook works well.
• Driving discussion: Be a supportive partner in the driving restriction conversation. This can be emotionally difficult but is critical for safety.
• Be patient: Even after medical clearance, the person may need time to regain confidence in their memory and daily activities.

• University of Utah Health Stroke Center: DNV-certified Comprehensive Stroke Center with 24/7 acute stroke care, advanced neuroimaging (including optimized hippocampal DWI protocols), and a large multistate TeleStroke network covering over 26 sites across the Mountain West. Academic vascular neurology with research infrastructure and clinical trials.
• Intermountain Medical Center (Murray): Joint Commission-certified Comprehensive Stroke Center with high regional volume, excellent door-to-needle performance, the Intermountain Neurosciences Institute providing vascular neurology, neurocritical care, epilepsy/functional surgery, neuropsychology, and a regional telehealth stroke program.
• Epilepsy Monitoring Units (EMU): Available at both University of Utah Health and Intermountain Neurosciences Institute for long-term video EEG monitoring, sleep-deprived EEG, and ambulatory EEG — essential for TEA workup.
• Cognitive Assessment Services: University of Utah Neuropsychology services provide detailed memory and cognitive evaluation, including specialized testing for accelerated long-term forgetting in TEA patients and post-TIA cognitive screening.
• TeleStroke Consultation: Both systems provide 24/7 acute stroke teleconsultation to community and rural facilities throughout Utah — critical for time-sensitive TIA triage outside major centers.

• Utah Driver License Division (DLD): Uses a Functional Ability / Safety Assessment Level framework. Seizures and episodic neurological conditions fall under Category E.
• After a seizure (including TEA): Typically requires a seizure-free interval of at least 3 months and physician evaluation before license reinstatement. Special considerations may apply for nocturnal-only or purely focal seizures.
• After TIA: Case-by-case assessment. Physician clearance via the Functional Ability Evaluation Medical Report (DLD-134) is typically required.
• Reporting: Utah generally relies on driver self-reporting and DLD-requested medical evaluations. There is no blanket mandatory physician-reporting requirement, though clinicians should counsel clearly and document discussions.
• Commercial drivers: Must meet stricter DOT/FMCSA medical standards.
• More information: dld.utah.gov/healthcare-providers (Functional Ability in Driving: Guidelines and Standards for Health Care Professionals)

• American Stroke Association: stroke.org — Information on TIA, stroke prevention, support groups, and the F.A.S.T. campaign.
• Epilepsy Foundation: epilepsy.com — Resources for seizure disorders including TEA, medication information, driving laws by state.
• FND Hope International: fndhope.org — Support and education for functional neurological disorder.
• UK Stroke Association: stroke.org.uk — Resources on TIA and rapid assessment pathways.
• TIME Project (TEA research): Research from the University of Exeter — the world’s largest TEA cohort and leading source of long-term outcome data.

• Advanced hippocampal MRI protocols: Higher-field MRI (3T and 7T) with thin-slice imaging improves detection of TGA-related hippocampal lesions. Research ongoing at academic centers.
• Ambulatory EEG and AI-assisted seizure detection: Wearable EEG devices and artificial intelligence algorithms are being developed to improve detection of subtle temporal lobe seizure activity, potentially transforming TEA diagnosis.
• Digital health tools: Smartphone apps for stroke risk monitoring, medication adherence, blood pressure tracking, and symptom logging are increasingly available and effective.
• Long-term cognitive outcomes research: Studies are tracking cognitive function in TGA and TEA patients over years — results so far are generally reassuring, showing stable cognition with appropriate treatment.
• FND-specific clinics: Specialized functional neurological disorder treatment programs are expanding, offering integrated physiotherapy, psychology, and neurology care for non-organic mimics.

Bring:

• A written timeline of the episode (when, how long, what happened)
• A witness who can describe what they observed
• Any video recordings from during the episode
• A complete medication list (including supplements and over-the-counter drugs)
• A list of your medical conditions and surgeries
• Your questions written down (use the “Questions to Ask” sections throughout this guide)
• A notebook to take notes during the appointment (or ask your companion to take notes)

Track between appointments:

• Any new episodes or unusual symptoms (date, time, duration, description)
• Blood pressure readings (at least weekly)
• Medication side effects
• Mood changes (anxiety, depression, sleep problems)
• Memory concerns (specific examples help more than general worry)

• FACE (Fast Assessment of Stroke and TIA to Prevent Early Recurrence): An international registry evaluating the effectiveness of rapid TIA clinics worldwide and whether urgent assessment consistently reduces stroke risk across different healthcare systems. Building on the original EXPRESS and SOS-TIA evidence.
• PRINCE (Platelet Reactivity in Clopidogrel/Ticagrelor): Studies examining whether genetic testing for CYP2C19 variants can guide the choice between clopidogrel and ticagrelor after TIA or minor stroke, personalizing antiplatelet therapy. This follows from the CHANCE-2 trial findings.
• NAVIGATE ESUS (NCT02313909): Completed trial that tested rivaroxaban versus aspirin for embolic stroke of undetermined source. Results did not show benefit over aspirin, helping refine which patients benefit from anticoagulation versus antiplatelet therapy after cryptogenic events.
• CRYSTAL-AF (NCT00924638): Showed that prolonged/continuous cardiac monitoring (an insertable cardiac monitor) detects far more occult atrial fibrillation after cryptogenic stroke or TIA than conventional follow-up. Finding AF changes treatment from antiplatelet to anticoagulant therapy.

• TIME Project (The Impairment of Memory in Epilepsy): Led by the University of Exeter (UK), this is the world’s largest and longest-running study of TEA. The TIME project has defined the clinical features of TEA, characterized accelerated long-term forgetting and autobiographical amnesia, and provided long-term outcome data showing stable cognition and normal life expectancy with treatment. Ongoing follow-up continues to refine understanding of interictal memory difficulties.
• ALF Research Programs: Multiple academic centers (Exeter, UCL Queen Square, Mayo Clinic) are studying accelerated long-term forgetting to develop better diagnostic tests and potential interventions. Current research focuses on whether memory compensation strategies (journals, digital reminders, spaced retrieval practice) can help patients whose ALF persists despite seizure control.

• Advanced hippocampal imaging studies: Research groups in Germany, South Korea, and Japan are using ultra-high-field MRI (7T) and optimized DWI protocols to better characterize the hippocampal lesions seen in TGA. These studies aim to understand why only the CA1 region is affected and whether lesion patterns predict recurrence.
• Venous congestion studies: Ongoing vascular research is evaluating the role of internal jugular vein valve incompetence in TGA using dynamic ultrasound and MR venography. While epidemiological associations are established, a causal mechanism remains unproven.

• ClinicalTrials.gov: The US National Library of Medicine’s database of clinical studies. Search for “transient ischemic attack,” “transient epileptic amnesia,” or “transient global amnesia.”
• StrokeNet (NIH/NINDS): A national network of stroke clinical trial centers. The University of Utah is a StrokeNet site. Visit strokenet.org for active stroke prevention trials.
• Epilepsy Foundation Clinical Trials Portal: epilepsy.com/clinical-trials — lists seizure disorder studies including those relevant to TEA.
• Ask your neurologist. Your specialist may know of local studies or registries at University of Utah Health or Intermountain that are not yet listed on public databases.

Important: Participation in a clinical trial does not mean you stop your current treatment. Most trials compare a new approach to the current standard of care. Your medical team will explain exactly what is involved before you decide.

• Antiplatelet or anticoagulant therapy for TGA DE-ADOPTED
  Because TGA was historically sometimes confused with TIA, some patients were started on blood thinners (aspirin, clopidogrel, or warfarin). Multiple long-term follow-up studies have shown that TGA is not a vascular event and does not increase stroke risk. Prescribing antithrombotics specifically for TGA exposes patients to bleeding risk without benefit.
• Anti-seizure medication for TGA DE-ADOPTED
  TGA is not a seizure. Treating TGA with anti-seizure drugs provides no benefit and adds side effects. However, if the diagnosis is actually TEA (recurrent, brief, on waking), anti-seizure medication is highly effective — the key is getting the diagnosis right.
• Prophylactic medication to prevent TGA recurrence FAILED
  No medication has been shown to prevent TGA from recurring. Because recurrence is uncommon (8–18%) and episodes are benign, the risks of any prophylactic medication outweigh the benefits. Reassurance remains the standard approach.

• Long-term dual antiplatelet therapy (DAPT beyond 21–30 days) FAILED
  The MATCH and SPS3 trials showed that extending dual antiplatelet therapy (aspirin plus clopidogrel) beyond the short-term window significantly increased major bleeding without additional stroke prevention benefit. Current guidelines limit DAPT to 21 days (CHANCE) or 30 days (THALES).
• Intracranial stenting for intracranial atherosclerosis FAILED
  The SAMMPRIS trial (2011) and CASSISS trial (2022) both demonstrated that aggressive medical management alone was superior to intracranial stenting for symptomatic intracranial stenosis. Stenting carried higher complication rates. Medical therapy (intensive antiplatelet, statin, blood pressure control) is now the standard.
• “Wait and watch” approach to TIA DE-ADOPTED
  Before the EXPRESS and SOS-TIA studies, many TIA patients were sent home with a routine outpatient neurology appointment weeks later. This approach was shown to miss the critical early treatment window, resulting in preventable strokes. Same-day or next-day specialist evaluation is now the global standard.
• ABCD2 score to defer urgent referral DE-ADOPTED
  The ABCD2 score was once used to decide which TIA patients needed urgent evaluation and which could wait. NICE NG128 now explicitly states that ABCD2 should not be used to delay referral, because low scores can miss high-risk conditions (carotid stenosis, atrial fibrillation, DWI-positive infarction).
• Warfarin for non-cardioembolic TIA FAILED
  The WARSS and ESPRIT trials established that warfarin is not superior to antiplatelet therapy for non-cardioembolic stroke/TIA and carries a higher bleeding risk. Warfarin (or DOACs) is reserved for cardioembolic sources such as atrial fibrillation.

• Rivaroxaban for embolic stroke of undetermined source (ESUS) FAILED
  NAVIGATE ESUS (NCT02313909) and RE-SPECT ESUS tested anticoagulants versus aspirin for cryptogenic embolic strokes. Neither trial showed benefit, and rivaroxaban increased bleeding. Aspirin remains standard unless a specific cardioembolic source (like AF) is found.
• Nootropics and “memory supplements” for post-TGA or TEA memory concerns FAILED
  Supplements marketed for memory enhancement (ginkgo biloba, phosphatidylserine, various “brain health” products) have not been shown to improve outcomes in TGA, TEA, or post-TIA cognitive impairment in controlled trials. The GEM trial (ginkgo biloba) showed no benefit for cognitive decline prevention. Money and effort are better spent on proven strategies: medication adherence, blood pressure control, exercise, and sleep.

In the United States, TIA management follows the AHA/ASA guidelines (2021 update), which recommend urgent specialist evaluation within 24 hours for all suspected TIA, brain imaging (preferably MRI with DWI), vascular imaging, and cardiac monitoring. Dual antiplatelet therapy (aspirin plus clopidogrel for 21 days) is recommended for high-risk non-cardioembolic TIA or minor stroke, based on the CHANCE and POINT trials.

For TEA, there are no FDA-specific guidance documents, as TEA is managed under general epilepsy treatment guidelines from the American Academy of Neurology (AAN) and the American Epilepsy Society (AES). Lamotrigine, levetiracetam, and sodium valproate are all FDA-approved anti-seizure medications used in TEA management. TGA requires no FDA-regulated treatment.

Driving restrictions after TIA or seizure (including TEA) are determined at the state level. Most states require a seizure-free interval of 3–12 months before driving privileges are restored.

The UK has some of the most clearly defined TIA pathways in the world. NICE guideline NG128 (Stroke and TIA in over 16s, updated 2022) mandates specialist assessment within 24 hours for all suspected TIA, explicitly stating that the ABCD2 score should not be used to defer referral. The guideline recommends immediate aspirin loading, urgent carotid imaging, and consideration of dual antiplatelet therapy.

TEA research is led primarily from the UK — the TIME project at the University of Exeter and Queen Square Epilepsy Group at UCL have defined the condition and its management. Anti-seizure medications used for TEA (lamotrigine, levetiracetam, sodium valproate) are all licensed by the MHRA. Sodium valproate carries a Pregnancy Prevention Programme requirement in the UK for women of childbearing potential.

DVLA driving regulations are stricter than many US states: after a seizure (including TEA), patients must be seizure-free for 12 months before driving a car (Group 1 license) and 5 years for heavy goods or passenger vehicles (Group 2). After TIA, a 1-month driving restriction applies for Group 1 licenses.

European Stroke Organisation (ESO) guidelines align closely with AHA/ASA recommendations for TIA, emphasizing urgent assessment and early secondary prevention. The ESO recommends dual antiplatelet therapy for 21–30 days after high-risk TIA or minor stroke. European guidelines also emphasize prolonged cardiac monitoring (at least 72 hours, ideally 30 days) to detect paroxysmal atrial fibrillation after cryptogenic TIA.

Germany’s Deutsche Gesellschaft für Neurologie (DGN) published a dedicated S1 TGA guideline in 2023, one of the few country-specific TGA guidelines worldwide, recommending MRI with DWI at 24–72 hours and emphasizing that TGA does not require antiplatelet or anticoagulant therapy.

All anti-seizure medications used for TEA are EMA-authorized. EU driving regulations for epilepsy follow the European Commission Directive 2006/126/EC, requiring 12 months seizure-free for Group 1 and 10 years seizure-free for Group 2 licenses, though member states may apply stricter rules.

The Japanese Stroke Society (JSS) and Japan Stroke Association guidelines place particular emphasis on intracranial atherosclerosis as a cause of TIA, which is more prevalent in East Asian populations than extracranial carotid stenosis. Intracranial vascular imaging (MRA or CTA) is routinely recommended alongside extracranial imaging.

The CHANCE-2 trial (2022) demonstrated that CYP2C19 loss-of-function alleles — more common in East Asian populations — affect clopidogrel metabolism, and ticagrelor-based dual antiplatelet therapy may be more effective in these patients. Japanese guidelines are incorporating pharmacogenomic considerations into TIA management.

Anti-seizure medications for TEA are PMDA-approved. Japanese driving law requires a 2-year seizure-free interval before driving is permitted after an epilepsy diagnosis. TGA is well-recognized in Japanese neurology, with significant research contributions on hippocampal DWI lesion detection using high-field MRI.

The Canadian Stroke Best Practice Recommendations (updated regularly by the Heart and Stroke Foundation of Canada) closely mirror AHA/ASA guidelines. Rapid TIA assessment pathways are well-established in major Canadian centers, with recommended specialist evaluation within 24 hours. The Canadian Best Practice Advisory recommends dual antiplatelet therapy for 21 days after high-risk TIA.

Health Canada has approved all major anti-seizure medications used for TEA. TEA diagnosis and management follow international epilepsy guidelines (ILAE).

Driving regulations are provincial. Most provinces require a 3–12 month seizure-free interval after a seizure diagnosis before driving privileges are restored. After TIA, provincial requirements vary but generally require physician clearance and demonstrated stability.

Australia’s Stroke Foundation Clinical Guidelines (2024 update) provide comprehensive TIA management recommendations aligned with international evidence. Australia has an extensive network of stroke units and TIA rapid-assessment pathways, particularly in metropolitan areas. Rural and remote access remains a challenge, with telehealth stroke consultation expanding to address geographic barriers.

All standard anti-seizure medications are registered with Australia’s Therapeutic Goods Administration (TGA — not to be confused with the neurological condition TGA). Austroads driving guidelines, adopted nationally, require a minimum 12-month seizure-free period for an unconditional private vehicle license after an epilepsy diagnosis, with provisions for conditional licenses in some circumstances.

• Driving restrictions after seizure: Range from 3 months (some US states) to 24 months (Japan), with most countries requiring 6–12 months seizure-free. Commercial driving restrictions are uniformly stricter.
• Pharmacogenomics: East Asian guidelines increasingly recommend CYP2C19 genotyping before choosing between clopidogrel and ticagrelor for TIA secondary prevention, following CHANCE-2 evidence. This is not yet routine in Western guidelines.
• Intracranial vs. extracranial focus: Western guidelines emphasize extracranial carotid stenosis screening after TIA. East Asian guidelines place greater emphasis on intracranial atherosclerosis, reflecting population-level differences in disease distribution.
• TGA-specific guidelines: Germany (DGN S1, 2023) is one of the few countries with a dedicated TGA clinical guideline. Most countries manage TGA under general neurology practice with no condition-specific regulatory guidance.
• Sodium valproate restrictions: The UK (MHRA) and EU (EMA) have implemented strict pregnancy prevention programs for sodium valproate. Similar restrictions exist in most developed countries, making lamotrigine or levetiracetam preferred first-line agents for TEA in women of childbearing potential worldwide.

• ABCD2 score — a clinical scoring tool (0–7) that estimates the short-term stroke risk after a TIA. Points are assigned for Age, Blood pressure, Clinical features, Duration, and Diabetes. Higher scores indicate greater urgency for workup and treatment.
• Accelerated long-term forgetting (ALF) — a memory pattern seen in TEA where new information is learned normally but fades much faster than expected over days to weeks, even though standard memory tests appear normal. Often the most troubling ongoing symptom for TEA patients.
• Anterograde amnesia — the inability to form new memories from the moment of onset forward. During a TGA episode, patients cannot retain new information even seconds after hearing it, leading to repetitive questioning.
• Anticoagulation — blood-thinning medication (such as warfarin, apixaban, rivaroxaban, or edoxaban) that prevents blood clots from forming; used after TIA when atrial fibrillation or another cardiac source of clots is identified.
• Antiplatelet therapy — medications (such as aspirin, clopidogrel, or ticagrelor) that prevent platelets from clumping together to form clots; a cornerstone of secondary stroke prevention after TIA when the cause is arterial rather than cardiac.
• Atrial fibrillation (AF or AFib) — an irregular heart rhythm originating in the upper chambers of the heart that allows blood to pool and form clots, which can travel to the brain and cause a TIA or stroke. Requires anticoagulation rather than antiplatelet therapy.

• Carotid stenosis — narrowing of the carotid arteries (the major blood vessels in the neck supplying the brain), usually from atherosclerotic plaque. Significant stenosis is a treatable cause of TIA and stroke, often managed with carotid endarterectomy or stenting.
• DWI-MRI (diffusion-weighted imaging) — a specialized MRI sequence that detects areas of restricted water movement in brain tissue, making it highly sensitive for identifying acute ischemic injury (stroke). Small DWI lesions in the hippocampus can appear 24–72 hours after TGA and help confirm the diagnosis.
• EEG (electroencephalogram) — a test that records the electrical activity of the brain using electrodes placed on the scalp. Essential for diagnosing TEA; sleep-deprived EEG or prolonged ambulatory EEG increases detection of epileptiform discharges that routine EEG may miss.

• Hodges–Warlow criteria — the standard diagnostic criteria for TGA, requiring: the attack must be witnessed by a capable observer; there must be clear-cut anterograde amnesia during the attack; no clouding of consciousness or loss of personal identity; no focal neurological symptoms; no epileptic features; the attack must resolve within 24 hours; and there must be no recent head injury or active epilepsy.
• Retrograde amnesia — loss of memories formed before the onset of the episode. In TGA, retrograde amnesia can extend back hours to days and typically shrinks as the episode resolves, though a permanent gap for the episode itself usually remains.

• Secondary prevention — medical strategies (medications, procedures, lifestyle changes) aimed at preventing a second TIA or stroke after the first event. Includes antiplatelet or anticoagulant therapy, blood pressure control, statin therapy, and management of modifiable risk factors.
• TEA (transient epileptic amnesia) — a form of temporal lobe epilepsy in which seizures present primarily as brief episodes of isolated amnesia, often occurring upon waking. Unlike TGA, episodes tend to recur and respond well to anti-seizure medication. Accelerated long-term forgetting and autobiographical amnesia are common between episodes.
• TGA (transient global amnesia) — a sudden, temporary episode of dense anterograde amnesia (inability to form new memories) typically lasting 1–10 hours. The patient remains alert and conversational but asks the same questions repeatedly. Resolves fully; recurrence is uncommon (~8–18% cumulative over long-term follow-up). Cause is not fully understood but is considered benign.
• TIA (transient ischemic attack) — a brief episode of neurological dysfunction caused by temporary interruption of blood flow to the brain, without lasting brain injury on imaging. Often called a “mini-stroke,” a TIA is a medical emergency and a warning of significantly elevated stroke risk in the following days and weeks. Demands urgent evaluation and secondary prevention.

Office blood pressure measurements can be misleading. "White coat hypertension" (BP elevated only in the doctor’s office) affects up to 20% of people, while "masked hypertension" (BP normal in office but elevated at home) affects another 10–15%. Home blood pressure monitoring provides far more data points, eliminates white-coat effect, and is now recommended as standard care for all patients on antihypertensive therapy. Guidelines for home monitoring:

• Use an upper-arm cuff device (not wrist cuffs, which are less accurate). Use a device validated by the American Medical Association validated device list (validatebp.org) or the European Society of Hypertension.
• Measurement protocol: Sit quietly for 5 minutes before measuring. Feet flat on floor, arm at heart level, back supported. Take 2 readings 1 minute apart. Average them. Measure morning (before medication, before breakfast) AND evening (before dinner). Do this for 7 days before each clinic visit and bring the log.
• Home target: Average home BP <125/75 mmHg corresponds approximately to office BP <130/80 mmHg. Ambulatory blood pressure monitoring (ABPM, worn for 24 hours) is the most accurate method; 24-hour average target <130/80 mmHg, daytime <135/85 mmHg, nighttime <120/70 mmHg.
• Share your home log with your neurologist and primary care physician at every visit. Many practices now accept home BP logs via their patient portal; document readings consistently.

• DASH diet (Dietary Approaches to Stop Hypertension): A diet pattern shown in RCTs to reduce systolic BP by 8–14 mmHg in hypertensive individuals. DASH emphasizes fruits, vegetables, whole grains, low-fat dairy, lean protein, and nuts while limiting saturated fat, red meat, and sodium. A DASH-sodium combination (DASH diet + <1,500 mg sodium/day) reduces systolic BP by up to 11–16 mmHg in some studies — equivalent to the effect of a single antihypertensive medication.
• Sodium reduction: The average American consumes ~3,400 mg sodium per day. Reducing to <2,300 mg (1 teaspoon salt equivalent) reduces systolic BP 2–6 mmHg; reducing further to <1,500 mg provides additional benefit. Read nutrition labels: bread, soup, deli meats, and restaurant food are the largest hidden sodium sources.
• Physical activity: 150 minutes/week of moderate aerobic exercise reduces systolic BP 4–8 mmHg in hypertensive patients. Resistance training (2–3 days/week) provides an additional 2–4 mmHg reduction. Walking, cycling, and swimming are low-impact options appropriate for most post-TIA patients.
• Weight loss: Each 1 kg (~2.2 lb) of weight loss reduces systolic BP by approximately 1 mmHg. For overweight TIA patients, even modest weight loss (5–10% of body weight) provides meaningful BP reduction without requiring extreme dietary restriction.
• Alcohol reduction: Reducing alcohol from >3 drinks/day to 1 drink/day lowers systolic BP 3–4 mmHg. Heavy alcohol use is a major contributor to resistant hypertension.
• Smoking cessation: Smoking acutely raises BP by 5–10 mmHg with each cigarette (nicotine effect); long-term smoking increases arterial stiffness and chronic BP elevation. Quitting smoking with pharmacological assistance (varenicline preferred; also NRT, bupropion) is the highest-yield single lifestyle modification for long-term vascular risk.

• Travel after TIA: Most TIA patients can travel safely once secondary prevention is established (usually within 4–8 weeks). Carry a complete medication list, extra supplies of all medications (at least one week beyond planned duration), and a medical summary from your neurologist. International travel: research healthcare access in destination countries. Travel insurance that covers pre-existing conditions is essential and must be arranged specifically — standard travel insurance often excludes pre-existing neurological conditions.
• Air travel: Flying is not contraindicated after TIA or TGA. Cabin pressure is maintained equivalent to 6,000–8,000 feet altitude — this is safe for most TIA patients. Long-haul flights increase DVT risk; stay hydrated, wear compression stockings, and take regular walks in the cabin. Patients on anticoagulation for AF-related TIA should discuss whether dose adjustment is needed for very long flights (>6 hours) with their cardiologist.
• Life insurance and health insurance after TIA: A TIA history must be disclosed on life insurance applications; premiums will typically increase. Some insurers will decline new life insurance for 1–2 years post-TIA. Health insurance through an employer plan (ERISA-governed) cannot discriminate based on pre-existing conditions (ACA protections). Individual market health insurance also cannot exclude pre-existing conditions. Disability insurance applications require TIA history disclosure and underwriting decisions vary by insurer and time since event.
• Advance care planning: After any neurological event, it is appropriate to review and update your advance directive (living will) and healthcare proxy designation, even if your current health is good. Discussing your values and preferences regarding resuscitation and neurological disability with loved ones and your primary care physician ensures that if future decisions must be made, they reflect your wishes.
• Staying vigilant: Commit to lifelong follow-up for blood pressure, lipid, and AF monitoring. Stroke risk after TIA is not zero long-term even with optimal treatment; it decreases substantially in the first year but remains elevated for life. Treat secondary prevention as a permanent lifestyle change, not a temporary course of treatment after a frightening event.

A second opinion from a vascular neurologist or comprehensive stroke center is appropriate when: the cause of the TIA remains unclear ("cryptogenic") after full workup; you are uncertain about the antiplatelet or anticoagulant regimen recommended; you are being evaluated for carotid endarterectomy or stenting; or you have had a recurrent TIA or stroke despite apparently adequate secondary prevention. Academic medical centers with Joint Commission-certified Comprehensive Stroke Centers (find them at strokeassociation.org/findastrokecenter) provide access to advanced diagnostic capabilities including high-resolution vessel wall MRI, cardiac CT, and multispecialty stroke boards for complex cases. Seeking a second opinion is not a sign of distrust in your current care team; it is standard practice for serious neurological events.

• Aspirin 81–325 mg daily: The foundational antiplatelet for stroke prevention. Irreversibly inhibits cyclooxygenase, preventing thromboxane A2-mediated platelet aggregation. Low dose (81 mg) is as effective as higher doses for stroke prevention and has lower GI bleeding risk. Take with food to reduce gastric irritation. Do not stop without telling your neurologist.
• Clopidogrel (Plavix) 75 mg daily: A P2Y12 ADP receptor antagonist. Preferred over aspirin for TIA patients in many European and UK guidelines (CAPRIE trial); in the US, used as alternative when aspirin cannot be tolerated or when CYP2C19 genetic testing confirms adequate metabolism. Note: approximately 25–30% of people have a CYP2C19 variant that reduces clopidogrel conversion to its active form; these "clopidogrel poor metabolizers" may require an alternative (prasugrel, ticagrelor) — ask your cardiologist about pharmacogenomics testing if prescribed clopidogrel.
• Dual antiplatelet therapy (DAPT) — aspirin + clopidogrel: The POINT trial and CHANCE trial demonstrated that short-term DAPT (21–90 days post-TIA) reduces early stroke recurrence risk by approximately 25% compared to aspirin alone, without significantly increased major bleeding. DAPT is now standard of care in most US academic centers for high-risk TIA (ABCD2 ≥4) for the first 21 days. After 21–90 days, DAPT is typically stepped down to single antiplatelet to reduce long-term bleeding risk.
• Anticoagulation (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban): Used instead of antiplatelets when TIA is caused by atrial fibrillation or other cardioembolic sources. For AF-related TIA, anticoagulation is far superior to antiplatelet therapy for stroke prevention. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) are now preferred over warfarin in AF-related TIA because they have similar or better efficacy, lower intracranial hemorrhage risk, and require no INR monitoring.
• What to avoid: NSAIDs (ibuprofen, naproxen) interfere with antiplatelet therapy; avoid regular use while on aspirin. Ginkgo biloba and high-dose fish oil increase bleeding risk when combined with antiplatelets. Always disclose all medications, supplements, and over-the-counter drugs to every member of your care team.

• High-intensity statins: Atorvastatin 40–80 mg or rosuvastatin 20–40 mg are the preferred agents for post-TIA lipid management. The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) demonstrated that atorvastatin 80 mg reduced stroke recurrence by 16% and major cardiovascular events by 20% in patients with recent TIA or stroke. Target LDL: <70 mg/dL (<1.8 mmol/L) or >50% reduction from baseline. Statins also have pleiotropic anti-inflammatory and vascular stabilizing effects beyond lipid lowering.
• Blood pressure management: Target SBP <130 mmHg in most TIA patients (AHA/ACC 2017 guidelines). ACE inhibitors (ramipril, lisinopril) and ARBs (losartan, candesartan) are preferred first-line agents because of their combined antihypertensive and vascular-protective effects. The PROGRESS trial showed that perindopril + indapamide reduced stroke recurrence by 43% in patients with prior stroke/TIA. Home blood pressure monitoring (morning and evening, averaging 3 readings) provides better blood pressure tracking than office-only measurements.

• Mindfulness-Based Stress Reduction (MBSR): An 8-week structured program developed at the University of Massachusetts Medical School; shown in multiple RCTs to reduce anxiety, depression, and perceived stress in neurological conditions. Particularly relevant for post-TIA anxiety and health anxiety after TGA. Available in-person through many hospital wellness centers and online via the MBSR online course (palousemindfulness.com).
• Aerobic exercise and neuroplasticity: Regular aerobic exercise (brisk walking 30 minutes, 5 days/week) stimulates BDNF (brain-derived neurotrophic factor), promotes hippocampal neurogenesis, and is the most robustly evidence-based non-pharmacological intervention for cognitive resilience in vascular risk populations. For TIA patients who have been cleared to exercise, this is a high-priority lifestyle modification.
• Sleep optimization: Chronic sleep deprivation (<7 hours/night) increases vascular risk, impairs cognitive function, and worsens memory consolidation. Post-TGA/TIA patients should prioritize sleep hygiene: consistent sleep/wake times, dark cool bedroom, no screens within 60 minutes of sleep, avoiding caffeine after 2 PM. CBT for insomnia (CBT-I) is the first-line treatment for insomnia and is superior to hypnotics in the long term.
• Social engagement and cognitive stimulation: Social isolation and cognitive inactivity are independently associated with accelerated cognitive decline in vascular risk populations. Maintaining and expanding social connections, engaging in cognitively stimulating activities (music, language learning, strategy games), and pursuing purposeful activities all appear to build cognitive reserve that buffers against vascular damage.
• What to avoid: High-dose fish oil supplements (>3 g EPA+DHA/day) may increase bleeding risk in patients on antiplatelets. Ginkgo biloba does not reduce stroke risk and may increase bleeding. High-dose vitamin E supplementation increases hemorrhagic stroke risk. Herbal products that inhibit CYP enzymes (St. John’s wort, valerian) can alter the metabolism of antiplatelet or anticoagulant medications — disclose all supplements to your neurologist and cardiologist.

• Mediterranean diet pattern: The PREDIMED trial (Prevención con Dieta Mediterránea) demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced stroke risk by 39% in high-cardiovascular-risk adults. The Mediterranean pattern emphasizes olive oil, fish, legumes, whole grains, vegetables and fruits, and limits red meat and processed foods. Following this pattern post-TIA is strongly evidence-supported.
• Sodium restriction: Target <2,300 mg sodium per day (approximately 1 teaspoon of salt) for blood pressure reduction. Each 1,000 mg reduction in daily sodium intake reduces systolic blood pressure by approximately 2–3 mmHg at a population level; in sodium-sensitive individuals the effect is larger.
• Potassium: Adequate dietary potassium (4,700 mg/day target; achievable through fruits, vegetables, legumes, and low-fat dairy) antagonizes sodium’s blood-pressure-raising effects and independently reduces stroke risk by approximately 11% per 1,000 mg increase in daily intake.
• Dietary fat: Reduce saturated fats (red meat, full-fat dairy, tropical oils) and eliminate trans-fats (partially hydrogenated oils). Replace saturated fat with unsaturated fat (olive oil, avocado, nuts, fish). Target LDL <70 mg/dL post-TIA; statins usually necessary alongside dietary measures.
• Alcohol: Limit to ≤1 drink/day for women, ≤2/day for men (or less). Heavy alcohol consumption raises blood pressure and triglycerides and increases AF risk. Moderate consumption has minimal net cardiovascular benefit in the context of established TIA risk.
• Hydration: Adequate hydration reduces blood viscosity and may reduce transient ischemic event risk from dehydration-induced hyperviscosity. Aim for pale yellow urine throughout the day; 1.5–2 L water daily in temperate climates, more in heat or with exercise.

For patients with TEA and documented Accelerated Long-Term Forgetting (ALF) — a pattern where memories that seem adequately formed soon after an event are lost within days to weeks — the following compensatory strategies are used clinically by neuropsychologists:

• Daily diary or structured memory journal: Recording important events, conversations, and information immediately after they occur (not hours later). Review the diary each morning as part of the waking routine. This external memory system compensates for the impaired biological consolidation process.
• Spaced repetition for important information: For information that needs to be retained long-term (medical information, names, important conversations), actively reviewing it at intervals (1 day, 3 days, 1 week, 1 month) exploits the spacing effect to reinforce memory traces that would otherwise fade in ALF.
• Environmental cues and routines: Consistent physical placement of important items (keys, medications, wallet); consistent daily routines that become procedural (immune to the hippocampal consolidation impairment); visual prompts (sticky notes, phone reminders, smart displays) at key locations for time-sensitive information.
• Digital tools: Smartphone reminder apps, voice memos recorded immediately after important conversations, calendar blocking with detailed notes (not just appointment titles), shared digital calendars with a trusted family member or caregiver who can update entries.
• Neuropsychological rehabilitation: If ALF is significantly impairing daily function, referral to a neuropsychologist specializing in memory rehabilitation for a formal Memory Compensation Program is appropriate. These programs are evidence-based, structured, and target the specific memory system most affected by the individual’s condition.

• CT scan of the brain (without contrast): Done immediately in virtually all presentations with acute neurological symptoms. Purpose: rule out hemorrhagic stroke, subdural hematoma, brain tumor, large ischemic infarct. CT is not sensitive for TGA or small TIA-related infarcts — it should be normal (or show only pre-existing changes) in TGA and in most TIAs.
• MRI of the brain with DWI: Diffusion-weighted imaging (DWI) is the gold standard for detecting acute ischemic infarction within hours of onset. It is also the test that shows hippocampal DWI lesions characteristic of TGA (seen in 60–70% of TGA patients, typically on delayed MRI 24–72 hours after the episode, not always on the initial MRI). An initial MRI done within 6 hours of TGA may be falsely negative for hippocampal changes. If the initial MRI is unremarkable and TGA is suspected clinically, a repeat MRI at 24–72 hours is standard at most academic stroke centers.
• Blood tests: Complete blood count (anemia, infection), comprehensive metabolic panel (electrolytes, glucose, BUN/creatinine, liver function), thyroid function (hypothyroidism causes cognitive slowing and confusion), coagulation studies if anticoagulation is being considered, lipid panel (TIA risk stratification). Blood glucose is measured immediately at triage to exclude hypoglycemia as a cause of confusion.
• ECG (12-lead): Routine in all acute neurological events. Looking for atrial fibrillation (a major source of cardioembolic TIA/stroke), other arrhythmias, prolonged QT. If AF is found on initial ECG, it changes the treatment pathway immediately (anticoagulation is more important than antiplatelet therapy).
• Cardiac monitoring: Continuous telemetry monitoring during the ED stay and/or hospital admission detects paroxysmal AF that may not be present on a single 12-lead ECG. After TIA, if the source remains cryptogenic (no clear cause identified), outpatient cardiac event monitoring for 30 days is recommended to detect paroxysmal AF.
• Vascular imaging: CT angiography (CTA) of the head and neck, or carotid duplex ultrasound, looks for carotid stenosis (a common TIA source) and intracranial vessel stenosis. This is part of the standard TIA workup but not TGA workup.
• Echocardiogram: Transthoracic echo (and sometimes transesophageal echo) looks for cardiac sources of embolism: intracardiac thrombus, patent foramen ovale (PFO), valvular disease, wall motion abnormalities from prior MI. Typically ordered as outpatient if not done urgently during admission.

• TGA: No universal US guideline exists. Most neurologists recommend 1-month abstention after a first TGA episode as a precaution; after full neurological evaluation confirms TGA and excludes seizures, driving typically resumes. Recurrent TGA may prompt longer restriction. Check state DMV regulations: some states require physician notification of neurological events; others leave it to patient discretion.
• TIA: Minimum one month driving restriction in most US states, often 3 months if there were residual deficits or a high ABCD2 score suggesting ongoing high risk. Commercial drivers have stricter regulations. Check your state’s DMV medical requirements.
• TEA (epilepsy driving laws): TEA is a seizure disorder, so epilepsy driving laws apply in all states. Restriction period varies by state but ranges from 3–12 months from the most recent seizure. After successful suppression with AEDs (no further amnestic episodes), most states will permit driving after the state-mandated seizure-free period. Your neurologist must provide documentation of seizure control status to the DMV in some states.

• Most patients with TGA can return to work within days to 1–2 weeks (pending follow-up and clearance) if their occupation does not involve driving or safety-critical decisions
• TIA patients can typically return to office work once secondary prevention is established and there are no residual cognitive or physical deficits; usually 2–4 weeks
• Occupations involving driving, operating heavy machinery, working at heights, commercial aviation, or medical procedures may require longer absence and may need formal occupational physician clearance
• If cognitive symptoms (concentration, memory, word-finding) persist after TIA, a formal neuropsychological evaluation documenting functional cognitive status may be needed to support a graduated return-to-work plan or workplace accommodation requests under the ADA
• FMLA (Family and Medical Leave Act) protects up to 12 weeks of unpaid leave for qualifying medical conditions, including TIA recovery; discuss with your employer’s HR department if an extended absence is anticipated

• Health anxiety after TGA: Even though TGA is benign, a significant proportion of patients develop persistent health anxiety in the months following an episode — hypervigilance to body sensations that might signal a recurrence, avoidance of situations or activities associated with the triggering episode, and intrusive worry about having a stroke. If health anxiety is significantly interfering with activities of daily living, short-term cognitive behavioral therapy (CBT) targeting health anxiety can be very effective and is well-studied for this indication.
• PTSD-like reactions after TIA: A TIA can be perceived as a near-death experience or "warning of dying soon," even when medically the prognosis is good. Some patients develop post-traumatic stress symptoms including intrusive memories of the TIA event, avoidance of reminders, hyperarousal, and emotional numbing. These symptoms respond to trauma-focused CBT and EMDR (eye movement desensitization and reprocessing).
• Depression after TIA/stroke: Post-stroke depression is a clinically established entity, distinct from a normal adjustment reaction. It affects approximately 30% of TIA/stroke patients in the first year and is associated with worse functional recovery, increased disability, and higher mortality. It requires active treatment (SSRIs, therapy, or both); it will not reliably self-resolve. Screening with the PHQ-9 at TIA/stroke follow-up appointments is recommended.
• Normal responses: Fear during and immediately after the event, relief at recovery, concern about recurrence, lifestyle adjustment stress. These are expected and do not require clinical intervention unless they persist beyond 4–6 weeks at impairing intensity.

Resources: The National Stroke Association (stroke.org), American Stroke Association (strokeassociation.org), and the TIA/amnesia sections of the Epilepsy Foundation (for TEA) all offer peer support groups, peer mentoring programs, and mental health referral guidance.

• What they witnessed: TGA is a temporary disruption of the brain’s memory-recording circuits, caused by a transient failure of memory-forming areas to function normally. The brain is not permanently damaged. It is not a stroke. It is not the beginning of dementia. Most people who have TGA never have another episode.
• Why repetitive questioning happened: During TGA, the person cannot form new memories. Every moment is forgotten almost as soon as it occurs. The repetitive questions ("What happened?" "Where are we?" "What day is it?") are not behavioral symptoms or personality change — they are the direct expression of the memory system failing to consolidate. Each time the person asks the question, it genuinely feels to them as though they are asking for the first time.
• What to do if it happens again: Stay calm, do not argue or try to correct the person about the date or circumstances, reassure them that they are safe, note the time the episode started, and take them to the nearest emergency department. If any stroke symptoms are present (facial weakness, arm weakness, speech difficulty), call 911 instead.
• Activity restrictions after TGA: Discuss with the neurologist, but most patients are advised to avoid triggers (strenuous Valsalva activities, sudden cold water immersion, extreme emotional distress) for a period after TGA. Most patients resume driving after 1 month if no recurrence.

• The warning sign framing: A TIA that resolved completely is a serious warning that stroke risk is significantly elevated in the days and weeks that follow. It is critically important that the patient take all prescribed medications consistently and attend all follow-up appointments. The lifestyle changes recommended (blood pressure, diet, exercise, smoking cessation) are genuinely life-saving, not just advisory.
• FAST/BE-FAST recognition: Every family member should know stroke warning signs and should not wait to see if symptoms improve before calling 911. Stroke treatment with tPA or mechanical thrombectomy is highly time-sensitive (tPA within 4.5 hours, thrombectomy within 6–24 hours depending on imaging); waiting an hour at home when symptoms are present eliminates treatment options.
• When to go vs. call the doctor: If new neurological symptoms develop — any weakness, speech difficulty, vision change, loss of balance, or severe headache — call 911 immediately, do not drive to the hospital, do not call the neurologist first. Time is brain.

Older adults presenting with a transient amnestic episode should have their medication list reviewed carefully before assuming the diagnosis is TGA. Several medication classes commonly used in older adults can cause acute confusional states, memory impairment, or amnesia-like presentations that may mimic TGA:

• Benzodiazepines and z-drugs (zolpidem, zaleplon): Can cause anterograde amnesia (inability to form new memories), particularly with higher doses or in elderly patients with reduced metabolism. Zolpidem-related "sleep-driving" and next-day amnestic episodes are well-documented. If a patient takes any of these drugs, correlate timing with the amnestic episode carefully.
• Anticholinergic medications: A broad class including bladder drugs (oxybutynin, solifenacin), older antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants, and some GI medications (dicyclomine). Anticholinergic burden in older adults causes acute cognitive impairment and can produce amnestic episodes. The Anticholinergic Cognitive Burden (ACB) scale identifies high-risk medications — cumulative anticholinergic burden is strongly associated with cognitive decline.
• Opioids: Particularly in opioid-naive older adults or with dose escalation, opioids can cause confusional episodes with amnestic features. Respiratory depression may also cause hypoxic insults that produce transient memory impairment.
• Statins: A small number of case reports and series link statins (particularly lipophilic statins: atorvastatin, simvastatin) to transient global amnesia-like episodes. The FDA added a memory/confusion warning to statin labels in 2012. The evidence is debated and the association appears rare, but it is worth reviewing statin dose and timing if an amnestic episode occurred after a recent statin start or dose increase.
• After hospitalization: Postoperative cognitive dysfunction (POCD) and delirium — common in older adults after major surgery — can present with amnestic features. These are distinct from TGA but may be confused with it in the perioperative period.

• Falls risk after TIA: The medications initiated for TIA secondary prevention (antihypertensives, antiplatelets) can each increase falls risk in older adults through orthostatic hypotension, dizziness, and bleeding risk from antiplatelet therapy. A falls risk assessment should be incorporated into TIA follow-up for older adults.
• Driving restrictions: All three conditions (TGA, TEA, TIA) may carry temporary or permanent driving restrictions depending on the state and severity. TGA: policies vary widely; many neurologists advise 1-month abstention after a first episode. TEA: seizure driving laws apply (typically 3–12 months seizure-free). TIA: typically one month minimum; may be extended if deficits persist or stroke risk remains very high. Discuss with your neurologist and check your state DMV regulations; some states mandate physician reporting of neurological events.
• Caregiver education for frail older adults: Family members or professional caregivers should be taught the distinguishing signs of TGA recurrence vs. new stroke symptoms. Stroke (BE-FAST: balance, eyes, face, arm, speech, time) requires immediate 911 activation; TGA (repetitive questions, anxious patient, preserved speech and motor function) is safer to transport to ED without 911 if the patient is stable.

Vascular cognitive impairment (VCI) encompasses a spectrum from mild vascular cognitive impairment to vascular dementia. TIA and stroke are significant risk factors for VCI, even when the acute event leaves no visible motor or sensory deficits. Several mechanisms contribute:

• Direct tissue loss from the ischemic event — even a small TIA-related infarct in a strategically important area (thalamus, frontal white matter tracts) can disrupt cognition disproportionate to its volume
• Underlying small vessel disease (white matter hyperintensities, lacunar infarcts visible on MRI) that often co-exists with TIA and contributes independently to cognitive risk
• Inflammation and disruption of the blood-brain barrier that may accelerate amyloid accumulation (the pathological hallmark of Alzheimer’s disease)

The risk of dementia after TIA is approximately 2–4 fold higher than in the general population without TIA history. The risk is highest in the first year after TIA and then declines but remains elevated for decades. Optimal secondary prevention (blood pressure, statins, antiplatelet therapy, atrial fibrillation treatment) reduces but does not eliminate the elevated risk.

• Baseline neuropsychological testing at 3–6 months after TIA (after the acute phase) provides a documented baseline against which future decline can be measured objectively. Standard office screening tools (MMSE, MoCA) are useful but less sensitive than formal neuropsychological assessment for detecting subtle early changes in memory, attention, and executive function.
• Brain-protective lifestyle: Physical exercise (the single most evidence-based cognitive protective intervention), Mediterranean diet pattern, social engagement, cognitively stimulating activities, treating depression (which both causes and accelerates cognitive decline), and consistent sleep (8 hours per night reduces amyloid accumulation) — all reduce cognitive decline risk in post-stroke populations.
• Aggressive cardiovascular risk management is also neuroprotective: blood pressure control, LDL reduction, diabetes management, smoking cessation, and atrial fibrillation treatment all reduce the incidence of additional ischemic events that compound cognitive damage.
• When to re-evaluate: If family members or the patient report memory lapses, confusion, word-finding difficulty, or personality changes that are new or worsening, a formal cognitive assessment should be requested. Early intervention in vascular cognitive impairment offers the best opportunity to slow progression.

Most patients with a first TGA episode require:

• Outpatient neurology follow-up within 4–8 weeks to review imaging results (DWI MRI), confirm diagnosis, discuss recurrence risk, address driving and activity restrictions, and assess psychological adjustment
• Subsequent follow-up: If MRI findings are consistent with TGA and there are no atypical features, many neurologists discharge patients from ongoing neurology follow-up after 1–2 visits with instructions to return if symptoms recur. No specific monitoring tests (serial MRIs, labs) are routinely required after TGA.
• Patient-initiated follow-up: If a second episode occurs, return to neurology promptly. While recurrence does not change the benign nature of TGA, it may prompt re-evaluation to confirm no alternative diagnosis was missed.

Post-TIA follow-up is active and structured because of the significant near-term stroke risk:

• Week 1–2 follow-up: With stroke neurologist or dedicated TIA clinic. Review all diagnostic workup, finalize antiplatelet (or anticoagulant) choice, confirm statin and blood pressure medications are optimally dosed and tolerated. If a 30-day cardiac event monitor was prescribed, schedule monitoring completion and review.
• One-month follow-up: Assessment of secondary prevention adherence, blood pressure control on home logs, lipid panel if available, review of cardiac monitor data if applicable.
• Three-month and six-month follow-up: Blood pressure and lipid panel to verify targets are met. Consider neuropsychological evaluation if cognitive symptoms have been reported.
• Annual follow-up (ongoing): Annual cardiovascular risk assessment, blood pressure and lipid monitoring, repeat echocardiography or vascular imaging if new symptoms develop, reassessment of antiplatelet/anticoagulation therapy as evidence evolves.
• Automatic return to ED for: Any new neurological symptoms — weakness, speech change, vision change, facial droop, sudden severe headache. These represent potential stroke and should trigger 911 activation, NOT a call to your neurologist’s office.

For Transient Epileptic Amnesia, follow-up mirrors epilepsy management generally:

• Neurology follow-up at 6–8 weeks to assess response to antiepileptic therapy (is it suppressing amnestic episodes?), review side effects, and determine whether dose adjustment is needed
• Annual follow-up to re-evaluate whether continued antiepileptic therapy is still needed; some patients attempt withdrawal after several seizure-free years under neurologist guidance
• Neuropsychological assessment to document and monitor Accelerated Long-term Forgetting (ALF), which persists in some TEA patients even when amnestic episodes are controlled
• Epilepsy-specific driving laws: in most US states, patients with epilepsy (including TEA) must be seizure-free for a defined period (typically 3–12 months, varies by state) before driving. After successful suppression of TEA episodes with medication, most patients can drive within this window. Regulations vary internationally.

• General neurologist: Evaluates and manages neurological conditions across a broad range of diagnoses. For most patients with TGA or uncomplicated TIA, a well-trained general neurologist is the appropriate first specialist. Confirms the diagnosis, orders imaging and workup, establishes the initial secondary prevention plan, and follows up.
• Vascular neurologist (stroke neurologist): A neurologist with additional training in cerebrovascular disease — stroke, TIA, and cerebrovascular malformations. For complex TIA cases (multiple recurrences, unusual imaging findings, cryptogenic TIA without identified cause), referral to a vascular neurologist or a stroke neurology service is appropriate. Most academic medical centers and stroke centers have vascular neurology subspecialists.
• Epileptologist: A neurologist with fellowship training in epilepsy. For Transient Epileptic Amnesia, a neurologist who specializes in epilepsy is the most appropriate specialist, particularly when EEG interpretation is complex, when first-line antiepileptic drugs fail, or when the diagnosis is uncertain. Epileptologists typically have access to video-EEG telemetry and a broader antiepileptic drug prescribing experience.
• Neuropsychologist: A psychologist specializing in the relationship between brain function and behavior. For patients with cognitive complaints after TGA, TEA, or TIA — including Accelerated Long-term Forgetting in TEA, post-TIA mood disorders, or health anxiety — neuropsychological assessment provides objective measurement of cognitive function and guides rehabilitation planning. Neuropsychologists also provide CBT and cognitive rehabilitation in many settings.
• Neurosurgeon: Involved when structural causes of TIA (carotid stenosis requiring surgical endarterectomy, AVM requiring resection, or unruptured aneurysm requiring clipping or coiling) are identified. Surgical decisions are made jointly between the vascular neurologist and neurosurgeon or interventional neuroradiologist.
• Interventional neuroradiologist / Endovascular neurosurgeon: Performs minimally invasive procedures through catheters threaded to the brain vasculature — including carotid artery stenting (CAS), patent foramen ovale (PFO) closure, and coiling of cerebral aneurysms. PFO closure in cryptogenic stroke/TIA in patients <60 years with right-to-left shunting is now supported by multiple randomized trials and may be discussed with appropriate patients.

Hypertension is the single most important modifiable risk factor for stroke. Every 10 mmHg reduction in systolic blood pressure is associated with approximately 40% reduction in stroke risk. After TIA or stroke, the target blood pressure in most guidelines is <130/80 mmHg. Practical strategies:

• Home blood pressure monitoring twice daily (morning and evening) provides more data and better control than office measurements alone. Share your log with your provider. Automatic cuff monitors are accurate and affordable.
• DASH diet: emphasizes fruits, vegetables, low-fat dairy, reduced saturated fat, and limited sodium. DASH diet adherence is associated with 5–11 mmHg systolic BP reduction in trials — comparable to a single antihypertensive medication.
• Sodium restriction to <2.3 g/day (less than 1 teaspoon of salt) is one of the most effective single dietary changes. Reading food labels for sodium content in processed foods, restaurant meals, and canned goods is essential.
• Regular aerobic exercise: 30+ minutes of moderate intensity on most days. Even walking significantly reduces blood pressure in hypertensive individuals.
• Alcohol moderation: >2 drinks/day significantly raises blood pressure. Reduction to ≤1/day (women) or ≤2/day (men) is recommended.
• If lifestyle measures are insufficient, antihypertensive medications are generally very well tolerated, cost-effective (most are generic), and highly effective.

• Diabetes management: Tight glucose control (HbA1c <7%) reduces microvascular complications and, over time, reduces atherosclerotic risk. After TIA, discuss glucose control with your neurologist and primary care provider as part of the comprehensive risk assessment.
• LDL cholesterol: After TIA, most patients are started on high-intensity statin therapy with LDL target <70 mg/dL, or even <55 mg/dL in recurrent TIA/stroke (per European guidelines). If LDL remains above target on maximum tolerated statin, ezetimibe and PCSK9 inhibitors (evolocumab, alirocumab) provide additional lowering.
• Smoking: Smoking approximately doubles stroke risk. Cessation is one of the most powerful secondary prevention interventions available. Combination pharmacotherapy (varenicline + nicotine replacement or bupropion + nicotine replacement) with behavioral support achieves 1-year quit rates of 25–35%. Your primary care provider can prescribe cessation medication.
• Atrial fibrillation: If AF is detected after TIA (at any time), anticoagulation replaces antiplatelet therapy as the primary stroke prevention strategy. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AF based on equivalent or superior efficacy with better safety profiles. The decision about which DOAC is made based on renal function, drug interactions, and patient preference.
• Obstructive sleep apnea (OSA): OSA is strongly associated with both AF and stroke risk. If you snore, have witnessed apneas, or have daytime sleepiness, ask your provider about a sleep study. CPAP therapy for OSA is associated with reduced stroke recurrence risk in retrospective data.

In the UK, the National Institute for Health and Care Excellence (NICE) publishes stroke and TIA guidelines (currently CG68 and its updates). The UK has invested significantly in the TIA clinic model: high-risk TIA patients are evaluated in dedicated rapid-access TIA clinics within 24 hours of symptom onset, a model associated with significant stroke reduction in the OAST trial and subsequent implementation data. Treatment protocols broadly mirror US guidelines: dual antiplatelet for high-risk TIA, early statin initiation, blood pressure management, and cardiac monitoring for AF. Clopidogrel is preferred over the aspirin+dipyridamole (Aggrenox) combination for long-term secondary prevention in NICE guidelines — a departure from some US practices. Carotid surgery for symptomatic stenosis is prioritized within 2 weeks of TIA/stroke in UK guidelines, consistent with international evidence.

European Stroke Organisation (ESO) guidelines for TIA and ischemic stroke are broadly concordant with US AHA/ASA guidelines. The main practical difference in European management is higher uptake of MR-based diagnosis over CT as the default acute imaging modality in countries with well-resourced MRI capacity.

Japanese stroke guidelines (Japan Stroke Society) generally align with international standards for TIA and secondary prevention. Japan has a high density of MRI scanners per capita, facilitating rapid MRI-based diagnosis. Aspirin dose preferences in Japan historically tended toward lower doses (81–100 mg) for secondary prevention, consistent with Asian population-specific pharmacokinetic data.

Driving restrictions after TGA and TIA vary significantly by country and even by jurisdiction within countries. In Australia, the AUSTROADS guidelines (adopted by most Australian states) recommend a 4-week driving restriction after TIA and specify that TGA is treated separately — many neurologists recommend 1–3 months off driving after a first TGA, though regulatory standards vary by state. In Canada, Canadian Stroke Guidelines recommend individual assessment of fitness to drive after TIA, with variable provincial implementation. Patients who drive for a living (commercial drivers) face stricter and longer restrictions in virtually all jurisdictions.

• American Stroke Association (stroke.org): Patient education, stroke support groups, stroke center locator, and the Let’s Talk About Stroke series of evidence-based fact sheets
• Stroke Association (UK, stroke.org.uk): UK-specific support services, helpline (0303 3033 100), care pathway guidance, and peer support network
• European Stroke Organisation (eso-stroke.org): Professional guidelines and patient-facing resources
• World Stroke Organization (world-stroke.org): Global stroke resources and international center locator
• Epilepsy Foundation (epilepsy.com): For patients with Transient Epileptic Amnesia — provides epilepsy management resources, driving guidance by US state, and peer support programs

A thunderclap headache is defined as a severe headache that reaches maximum intensity within 60 seconds of onset — often described as "the worst headache of my life" or like being "hit on the head." This symptom is a neurological emergency until proven otherwise, because the most dangerous cause is subarachnoid hemorrhage (bleeding from a ruptured brain aneurysm), which is fatal in approximately 30–40% of cases. Other causes of thunderclap headache include reversible cerebral vasoconstriction syndrome (RCVS), cerebral venous sinus thrombosis, and hypertensive emergency.

Do NOT confuse thunderclap headache with a TGA trigger. While vomiting, straining, or sexual activity can trigger both TGA and subarachnoid hemorrhage, the headache in subarachnoid hemorrhage is instantaneous and catastrophic, not a mild discomfort. If the headache IS the dominant symptom — overwhelming, instantaneous, "the worst ever" — this is a 911 emergency, not a TGA.

Emergency evaluation for thunderclap headache requires non-contrast CT head (to detect blood in the subarachnoid space) and, if CT is negative, a lumbar puncture looking for xanthochromia (yellow discoloration of the CSF indicating blood breakdown). A negative CT alone is insufficient to rule out subarachnoid hemorrhage, particularly if performed more than 6 hours after headache onset. CT angiography or MR angiography may be performed to look for the causative aneurysm. Thunderclap headache with subarachnoid hemorrhage is a neurosurgical emergency.

Use the BE-FAST acronym to recognize stroke symptoms requiring immediate 911 activation:

• B — Balance: Sudden loss of balance or coordination
• E — Eyes: Sudden vision loss or double vision in one or both eyes, sudden visual field loss
• F — Face: Sudden facial droop or asymmetry (ask the person to smile — one side drags)
• A — Arms: Sudden arm weakness (one arm drifts down when both are raised) or sudden weakness or numbness in an arm, leg, or one side of the body
• S — Speech: Sudden slurred speech, inability to find words, inability to understand speech
• T — Time: Time to call 911 immediately. Note the time of symptom onset — this determines tPA and thrombectomy eligibility

Key point for TGA witnesses: In TGA, the patient is fully awake, walking and talking normally, with no weakness, facial droop, slurred speech, or vision loss. They are confused and amnestic, but their motor and speech function are intact. The presence of any BEFAST symptoms alongside confusion indicates a more dangerous event than TGA and requires 911 immediately. Similarly, any episode where confusion does NOT fully resolve within 24 hours requires urgent re-evaluation — TGA is by definition transient.

Witnessing a TGA episode is frightening because the person seems confused and keeps repeating questions, and you cannot be certain what is happening. The following steps are recommended:

1. Call emergency services (911 in the US) immediately if: the person has facial droop, arm weakness, speech difficulty, severe headache ("worst of my life"), or if the episode does not start resolving within 60 minutes. These features raise concern for stroke and demand urgent evaluation.
2. Do not leave the person alone. They cannot form new memories and cannot safely navigate, drive, or manage medication.
3. Stay calm, speak reassuringly, and repeat key information. Tell them who you are, where they are, and that they are safe. They will ask repeatedly — answer each time without frustration. Do not try to quiz them, test their memory, or show distress.
4. Prevent the person from driving. Even if they insist they are fine, they are not able to safely drive during an episode of severe anterograde amnesia.
5. Go to the emergency department even if the episode resolves. The first episode of amnesia requires evaluation to distinguish TGA from TIA, TEA, and other causes. This is not a decision to make at home.
6. Note the time and duration of the episode, any triggers immediately beforehand (strenuous activity, sexual intercourse, cold water, emotional stress, Valsalva maneuvers), and any other symptoms (headache, visual changes, weakness). This information is valuable to the medical team.

After a TGA, TIA, or TEA episode, your neurologist should review your medication list. Several classes of drugs can independently impair memory or cause confusion, and their effects may be misattributed to recurrent neurological events. Medications with clinically significant memory/cognitive effects include:

• Benzodiazepines (diazepam, lorazepam, clonazepam, alprazolam): cause anterograde amnesia and cognitive slowing, particularly in older adults. Even at standard prescribed doses, chronic benzodiazepine use causes measurable cognitive impairment. Consider whether the benefit-risk balance still favors continued use.
• Anticholinergic drugs (oxybutynin, tolterodine, diphenhydramine, tricyclic antidepressants, first-generation antihistamines, some antipsychotics): the "anticholinergic burden" from multiple medications is an underappreciated cause of memory problems in older adults.
• Opioids: Chronic opioid use causes cognitive impairment including attention and memory effects, particularly at higher doses or with combined benzodiazepine use.
• Certain antiepileptic drugs (phenobarbital, phenytoin, topiramate at higher doses, and to a lesser extent levetiracetam): can cause cognitive and memory side effects.
• Statins: Rare reports of memory/cognitive complaints associated with statin use have been publicized. The FDA added a label warning in 2012. However, large epidemiological studies have not found consistent evidence that statins worsen cognitive outcomes at population level; some studies suggest long-term statin use may reduce dementia risk. If you notice memory changes after starting a statin, discuss it with your provider, but do not stop a statin prescribed for TIA secondary prevention without guidance.

Bring your complete medication list — including all over-the-counter drugs, supplements, and sleep aids — to your neurology follow-up and ask for an explicit review of anticholinergic burden.

• What is my specific diagnosis — TGA, TEA, or TIA? If you’re not sure, what is the most likely diagnosis and what additional testing is needed?
• What is my actual recurrence risk? As a number, not "it’s unlikely."
• What are the specific driving restrictions I need to follow, and for exactly how long?
• Are there activities or Valsalva triggers I should avoid? Is there actually evidence that avoiding them reduces recurrence risk?
• Do I need any treatment? If TIA: which antiplatelet agent do you recommend and why? Is there any role for anticoagulation?
• Does my family need to do anything if I have another episode?
• Should I be referred to a neuropsychologist for formal cognitive testing?
• At what symptoms should I go directly to the emergency department vs. calling your office?

The most widely supported hypothesis for TGA is that a brief episode of increased venous pressure — from a Valsalva maneuver (sustained pressure increase against a closed glottis, as during straining, heavy lifting, sexual intercourse, or vomiting) — causes transient retrograde jugular venous flow that generates venous hypertension in the deep cerebral venous drainage system, specifically affecting the internal cerebral veins and straight sinus that drain the hippocampi. This transient venous congestion in the hippocampi is thought to cause the functional disruption of memory encoding that characterizes TGA.

Evidence supporting this hypothesis:

• A significant proportion of TGA episodes (approximately 30–50% in various case series) are preceded by an identifiable Valsalva-like trigger (straining, exercise, sexual activity, cold water exposure, emotional stress)
• Jugular venous reflux on Doppler ultrasound is found in a higher proportion of TGA patients than controls
• Incompetent jugular venous valves (which normally prevent retrograde venous flow) are found more commonly in TGA patients
• The diffusion-restricted hippocampal lesions on MRI appear later (24–72 hours) rather than immediately — consistent with delayed hippocampal injury from venous congestion rather than arterial ischemia (which would appear immediately on DWI)

The cortical spreading depression hypothesis — that TGA represents a spreading wave of neuronal depolarization analogous to migraine aura, originating in the hippocampus — was proposed as an alternative mechanism and may explain the association between TGA and migraine history in some patients. These two mechanisms are not mutually exclusive.

The hippocampus is the brain’s primary memory-encoding structure — it transforms short-term information into long-term memories, provides the context for autobiographical memory, and supports spatial orientation and navigation. Its unique vulnerability to hypoxia and ischemia (and apparently to transient venous congestion) is well established: the hippocampus is one of the first regions to show damage after cardiac arrest, severe hypoglycemia, or severe status epilepticus. In TGA, the transient functional disruption of hippocampal encoding explains the characteristic features — inability to form new memories (anterograde amnesia), relative preservation of immediate (working) memory (so the patient can carry on a conversation), and preservation of procedural memory (driving, playing an instrument, performing habitual tasks).

The repeated questioning ("Where are we?", "How did we get here?") that characterizes TGA is explained by the patient’s anterograde amnesia: they receive the answer to their question but cannot retain it, so they ask again. This behavior is distressing for witnesses but reflects a specific and temporary circuit failure rather than confusion about identity or global cognitive impairment.

• Stroke or hemorrhagic stroke: Infarction in the hippocampus, thalamus (especially the dorsomedial nucleus), or medial temporal lobes can cause permanent memory impairment that may initially look like TGA. The key difference: in true TGA, the episode fully resolves within 24 hours and the patient recovers to their baseline. Persistent memory deficits beyond 24 hours should prompt urgent re-evaluation.
• Non-convulsive status epilepticus (NCSE): Prolonged subclinical seizure activity can cause sustained confusion and memory impairment without visible convulsions. NCSE can be life-threatening and requires urgent EEG for diagnosis. It should be considered when "TGA" is unusually prolonged (>12 hours), or when the patient shows fluctuating but not fully resolving consciousness.
• Wernicke’s encephalopathy: Thiamine (vitamin B1) deficiency — most often from chronic alcohol use, but also from prolonged vomiting, malnutrition, or post-bariatric surgery — causes an acute encephalopathy including confusion, memory impairment, oculomotor abnormalities (nystagmus, ophthalmoplegia), and gait ataxia. Readily treatable with IV thiamine; missed diagnosis leads to permanent Korsakoff syndrome. Always considered in patients with alcohol use history who present with acute memory impairment.
• Metabolic encephalopathy: Hypoglycemia, hyponatremia, hypercalcemia, and hepatic or uremic encephalopathy can cause acute confusion that resolves when the metabolic abnormality is corrected. Standard bloodwork (glucose, electrolytes, renal function, liver function) rules these out.
• Drug or medication effects: Benzodiazepines, opioids, anticholinergic drugs, and alcohol can all cause acute confusional states with anterograde amnesia (inability to form new memories). Medication review is part of every acute amnesia workup. Notably, drug-induced amnesia — including "blackout" episodes — does not cause the repetitive questioning characteristic of TGA.
• Psychogenic amnesia / Functional neurological disorder: In rare cases, acute amnesia is functional (psychologically-mediated) rather than neurological. Distinguishing features include: amnesia for autobiographical identity (patient cannot remember who they are) — which does not occur in TGA — and the psychological context of the episode. Neurology and neuropsychiatry input is needed.
• Herpes encephalitis: HSV encephalitis preferentially targets the temporal lobes and hippocampus, causing acute onset of fever, headache, confusion, and sometimes seizures. It can be confused with severe TGA in an atypical presentation. Urgent CSF examination (herpes PCR) and IV acyclovir are indicated when encephalitis is on the differential. HSV encephalitis without fever is rare but possible in immunocompromised patients.
• Posterior reversible encephalopathy syndrome (PRES): Associated with hypertensive emergency, immunosuppression, or pre-eclampsia, PRES can cause acute confusion and memory symptoms with characteristic white matter changes on MRI FLAIR imaging.

A non-contrast CT scan is usually the first imaging done in the emergency setting because it is fast, widely available, and effectively rules out hemorrhagic stroke, large ischemic stroke, and brain tumors. For TGA and TIA, CT is usually normal — ischemic changes in TIA are often invisible on CT in the acute period. MRI with DWI (diffusion-weighted imaging) is the gold standard for detecting ischemic stroke and is usually arranged within 24 hours (or immediately if TIA is suspected). In TGA, MRI with DWI obtained 24–72 hours after the episode shows characteristic tiny punctate diffusion-restricted lesions in the hippocampus in 60–80% of cases — these represent transient reversible injury to the memory-encoding circuits. These lesions are not associated with permanent damage and resolve on follow-up imaging, but their characteristic bilateral hippocampal pattern is now recognized as strongly supportive of TGA diagnosis. An MRI done within the first few hours of a TGA episode may be negative even though lesions will appear later.

Electroencephalogram (EEG) records electrical brain activity and is the most important test for diagnosing Transient Epileptic Amnesia. Standard awake EEG is often normal in TEA because TEA episodes usually occur during sleep or upon waking, and inter-ictal epileptiform activity may not be present during a daytime EEG. A sleep-deprived EEG or prolonged ambulatory EEG over 24–72 hours increases detection sensitivity. If TEA is strongly suspected and standard EEG is negative, discussion with a specialist epileptologist about video-EEG telemetry may be appropriate. In TGA, EEG is almost invariably normal — the transient memory impairment in TGA is vascular/hemodynamic in origin, not epileptic. An abnormal EEG during a suspected TGA episode should prompt reconsideration of the diagnosis toward TEA.

After TIA, an urgent cardiac evaluation is essential to identify embolic sources that could produce another stroke. The standard workup includes:

• 12-lead ECG: Immediate — detects existing atrial fibrillation or flutter that immediately changes management (anticoagulation replaces antiplatelet therapy)
• Telemetry or Holter monitor (24–48 hours to 30 days): Paroxysmal AF occurs in only 3–7% of TIA patients acutely, but prolonged monitoring (30 days) detects AF in an additional 15–25%. For cryptogenic TIA/stroke where no obvious cause is found, an implantable loop recorder (ILR) for 3 years detects AF in 30%+ of patients.
• Echocardiogram (transthoracic or transesophageal): Looks for structural cardiac sources of emboli: patent foramen ovale (PFO, present in ~25% of the general population, but enriched in cryptogenic TIA patients), left atrial thrombus, valvular disease, or poor wall motion
• Carotid ultrasound or CT/MR angiography: Evaluates carotid stenosis, which drives decisions about carotid endarterectomy
• Standard bloodwork: CBC (polycythemia, thrombocytosis), coagulation studies, glucose, lipids (LDL target <70 mg/dL after TIA), HbA1c

In TGA, cardiac evaluation is typically less intensive — a standard 12-lead ECG and routine bloods are usually sufficient unless there is specific clinical suspicion of a cardiac cause.

• Health anxiety and hypervigilance: After a frightening event, it is natural to become acutely aware of bodily sensations — headaches, mild confusion, momentary forgetfulness — that would previously go unnoticed. This hypervigilance can itself amplify anxiety and lead to unnecessary emergency department visits. Cognitive behavioral strategies to "de-catastrophize" these sensations are helpful.
• Fear of recurrence: Even in TGA, where recurrence risk is genuinely low (3–5% per year), the fear of having another episode can be disproportionate to the actual risk. Asking your neurologist for a frank discussion of your specific recurrence risk — not just a reassuring "it’s probably fine" but a specific number — is an important step. Many patients find that quantified reassurance is more calming than vague optimism.
• Witness and family distress: Partners, family members, and friends who witnessed the episode often have significant distress of their own — in some cases, more than the patient (who typically does not recall the episode). Family education about what happened, what it means, and what to do if it recurs is as important as educating the patient.
• Grief and identity adjustment: For some patients, particularly after TIA with a confirmed stroke risk factor, there is a significant psychological adjustment to "now I am a person at risk for stroke." This adjustment takes time and support. Depression and anxiety after TIA are common and should be screened for at follow-up visits.
• Return to work and driving: Restrictions on driving (and sometimes on certain work activities involving machinery, heights, or safety-critical roles) are practically and psychologically challenging. Having a clear, time-limited plan from your neurologist — "we will re-assess in 3 months" — is much easier to cope with than an open-ended restriction with no clear return criteria.

If you are experiencing persistent anxiety, depression, sleep disruption, or avoidance behaviors after your neurological episode, ask for a referral to a clinical psychologist or neuropsychologist with experience in acquired neurological conditions. Brief CBT is effective for post-neurological anxiety.

Transient Global Amnesia has an excellent prognosis. The episode itself is self-resolving, memory typically fully recovers within 24 hours, and there are no known permanent brain changes attributable to TGA in neuroimaging follow-up studies. Recurrence risk for TGA is approximately 3–5% per year — meaning 95%+ of people who have one TGA episode will never have another. In the small group who do recur, most have only 2–3 lifetime episodes. TGA does not increase the risk of stroke or dementia. Long-term cognitive studies comparing TGA patients to matched controls have not shown differences in memory function or cognitive decline at follow-up of 5–10 years.

The main issue after TGA is psychological: the experience is frightening for the patient and for witnesses, and anxiety about recurrence is common even when recurrence risk is low. Some patients develop health anxiety, avoid triggers (which is usually unnecessary), or restrict activities unnecessarily out of fear. This anxiety can be more disabling than any recurrent neurological risk. Brief CBT or a consultation with a neuropsychologist familiar with TGA can be very helpful in this context.

Driving after TGA: Most neurologists and most state laws recommend a driving restriction of 1–3 months after a first TGA episode. The rationale is the small risk of recurrence and the theoretical hazard of sudden memory impairment while driving. After a recurrence-free period, most patients are cleared to resume driving. Guidance varies by jurisdiction and physician preference — always ask your neurologist for specific advice.

Transient Ischemic Attack carries a fundamentally different prognosis: it is a warning sign of imminent stroke. Without treatment, the 90-day risk of stroke after TIA is estimated at 10–15%. With prompt treatment, this risk falls substantially — studies of rapid TIA clinics show 80% reduction in 90-day stroke risk with rapid initiation of antiplatelet therapy, blood pressure control, statin initiation, and investigation for atrial fibrillation or carotid stenosis. The ABCD2 score (Age, Blood Pressure, Clinical features, Duration, Diabetes) was widely used to risk-stratify TIA patients; more recent evidence supports imaging-first evaluation (DWI-MRI and vascular imaging) regardless of ABCD2 score because of the high rate of positive findings even in apparently low-risk patients.

Key secondary prevention interventions after TIA include:

• Antiplatelet therapy: Dual antiplatelet therapy (aspirin + clopidogrel) for the first 21 days reduces subsequent stroke risk more than aspirin alone in high-risk TIA (POINT trial, CHANCE trial). After 21 days, single-agent antiplatelet therapy (aspirin or clopidogrel) is continued long-term.
• Statin initiation: Even without established hyperlipidemia, high-intensity statin therapy (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) is recommended after TIA to reduce stroke risk through plaque-stabilizing and anti-inflammatory effects beyond LDL reduction.
• Blood pressure control: Target <130/80 mmHg. Delayed initiation (24–72 hours after TIA) is generally recommended to avoid hypoperfusion in an already vulnerable vascular territory.
• Atrial fibrillation screening: Prolonged cardiac monitoring (30-day event monitor or implantable loop recorder) to detect paroxysmal AF, which requires anticoagulation rather than antiplatelet therapy.
• Carotid intervention: If 50%+ stenosis of the ipsilateral carotid artery is found, carotid endarterectomy (CEA) or carotid artery stenting (CAS) within 2 weeks of TIA significantly reduces recurrent stroke risk.

Transient Epileptic Amnesia typically responds well to antiepileptic drug therapy. In the largest published series (the TIAA study from the UK), about 80% of TEA patients had complete or near-complete suppression of amnestic episodes with lamotrigine or levetiracetam. This is excellent news — TEA is one of the more treatment-responsive forms of temporal lobe epilepsy. Driving restrictions after a first TEA episode are the same as for any first seizure: typically 6 months seizure-free in the UK (varies by country). After successful medical control, most patients can resume driving. The more challenging aspect of TEA is the inter-ictal cognitive syndrome: even between episodes, many TEA patients report Accelerated Long-term Forgetting (ALF) — the ability to form new memories normally on short tests but inability to retain them beyond days to weeks. This is poorly understood, likely reflects sub-clinical epileptiform activity during sleep, and is an active area of research. Neuropsychological assessment is recommended to document ALF and guide accommodation needs at work or school.